Skip to main content
. 2019 Dec;11(12):4972–4981. doi: 10.21037/jtd.2019.12.23

Figure 2.

Figure 2

Survival curves. (A) Kaplan-Meier estimate of progression-free survival for patients treated with salvage chemotherapy; (B) Kaplan-Meier estimates of post-progression survival for patients treated with salvage chemotherapy (blue line) and for patients treated with pembrolizumab beyond progression (red line).